Essex Investment Management Co. LLC Has $2.18 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Essex Investment Management Co. LLC trimmed its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 14.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 231,214 shares of the biopharmaceutical company's stock after selling 37,529 shares during the period. Essex Investment Management Co. LLC owned approximately 0.08% of Amicus Therapeutics worth $2,178,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. HealthInvest Partners AB grew its stake in Amicus Therapeutics by 18.6% in the fourth quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company's stock valued at $3,076,000 after acquiring an additional 51,368 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock valued at $255,936,000 after purchasing an additional 2,856,101 shares in the last quarter. Tempus Wealth Planning LLC acquired a new position in shares of Amicus Therapeutics in the 4th quarter valued at approximately $259,000. Neo Ivy Capital Management acquired a new position in shares of Amicus Therapeutics in the 3rd quarter valued at approximately $702,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in Amicus Therapeutics by 51.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company's stock worth $2,381,000 after purchasing an additional 75,807 shares in the last quarter.

Remove Ads

Analysts Set New Price Targets

Several research analysts have recently weighed in on FOLD shares. StockNews.com cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company reduced their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. Finally, Morgan Stanley reiterated an "equal weight" rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $16.75.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock traded down $0.08 during trading on Thursday, reaching $8.81. 1,666,927 shares of the company's stock were exchanged, compared to its average volume of 2,351,068. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics, Inc. has a 1-year low of $8.55 and a 1-year high of $12.65. The company has a market cap of $2.71 billion, a P/E ratio of -48.94, a PEG ratio of 1.51 and a beta of 0.69. The firm's 50-day moving average price is $9.40 and its 200 day moving average price is $10.19.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.